FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998957807> ?p ?o ?g. }

• W1998957807 endingPage "7142" @default.
• W1998957807 startingPage "7138" @default.
• W1998957807 abstract "Abstract Purpose: The primary goal of this trial was to determine the response rate of single-agent vorinostat in patients with metastatic breast cancer. The secondary goals included assessment of time to progression, evaluation of toxicities, and overall survival. Experimental Design: From June 2005 to March 2006, 14 patients received vorinostat, 200 mg p.o., twice daily for 14 days of each 21 day cycle. Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results: The median age for all patients was 60.5 years (range, 37-88). Eight patients were estrogen receptor and/or progesterone positive, four were Her-2 positive. Sites of metastatic disease included brain, liver, lungs, bones, pelvis, pleura, chest wall, and distant lymph nodes. Patients received a median of 1.5 prior (range, 0-2) chemotherapeutic regimens for metastatic disease. Fatigue, nausea, diarrhea, and lymphopenia were the most frequent clinically significant adverse effects. The median number of cycles delivered was 2 (range, 1-20). There were no complete or partial responses, and the study was terminated after the first stage; however, 4 patients were observed with stable disease with time to progression of 4, 8, 9, and 14 months. The median number of months that patients received treatment on this study was 1.7 (range, 0.5-14). Conclusions: Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken." @default.
• W1998957807 created "2016-06-24" @default.
• W1998957807 creator A5002013432 @default.
• W1998957807 creator A5018527792 @default.
• W1998957807 creator A5021183845 @default.
• W1998957807 creator A5023917993 @default.
• W1998957807 creator A5030731004 @default.
• W1998957807 creator A5036091074 @default.
• W1998957807 creator A5041200743 @default.
• W1998957807 creator A5056569468 @default.
• W1998957807 creator A5058936977 @default.
• W1998957807 creator A5059923524 @default.
• W1998957807 creator A5082853715 @default.
• W1998957807 creator A5086123605 @default.
• W1998957807 creator A5088012470 @default.
• W1998957807 date "2008-11-01" @default.
• W1998957807 modified "2023-10-01" @default.
• W1998957807 title "A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study" @default.
• W1998957807 cites W1504303645 @default.
• W1998957807 cites W1812576394 @default.
• W1998957807 cites W1875950880 @default.
• W1998957807 cites W1978664410 @default.
• W1998957807 cites W2027091400 @default.
• W1998957807 cites W2043721269 @default.
• W1998957807 cites W2081036615 @default.
• W1998957807 cites W2086384126 @default.
• W1998957807 cites W2099440961 @default.
• W1998957807 cites W2102169774 @default.
• W1998957807 cites W2103789449 @default.
• W1998957807 cites W2105457070 @default.
• W1998957807 cites W2107464631 @default.
• W1998957807 cites W2128985829 @default.
• W1998957807 cites W2135619784 @default.
• W1998957807 cites W2135830745 @default.
• W1998957807 cites W2151016906 @default.
• W1998957807 cites W2157795344 @default.
• W1998957807 cites W2160173183 @default.
• W1998957807 cites W4294107304 @default.
• W1998957807 doi "https://doi.org/10.1158/1078-0432.ccr-08-0122" @default.
• W1998957807 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3543872" @default.
• W1998957807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18981013" @default.
• W1998957807 hasPublicationYear "2008" @default.
• W1998957807 type Work @default.
• W1998957807 sameAs 1998957807 @default.
• W1998957807 citedByCount "202" @default.
• W1998957807 countsByYear W19989578072012 @default.
• W1998957807 countsByYear W19989578072013 @default.
• W1998957807 countsByYear W19989578072014 @default.
• W1998957807 countsByYear W19989578072015 @default.
• W1998957807 countsByYear W19989578072016 @default.
• W1998957807 countsByYear W19989578072017 @default.
• W1998957807 countsByYear W19989578072018 @default.
• W1998957807 countsByYear W19989578072019 @default.
• W1998957807 countsByYear W19989578072020 @default.
• W1998957807 countsByYear W19989578072021 @default.
• W1998957807 countsByYear W19989578072022 @default.
• W1998957807 countsByYear W19989578072023 @default.
• W1998957807 crossrefType "journal-article" @default.
• W1998957807 hasAuthorship W1998957807A5002013432 @default.
• W1998957807 hasAuthorship W1998957807A5018527792 @default.
• W1998957807 hasAuthorship W1998957807A5021183845 @default.
• W1998957807 hasAuthorship W1998957807A5023917993 @default.
• W1998957807 hasAuthorship W1998957807A5030731004 @default.
• W1998957807 hasAuthorship W1998957807A5036091074 @default.
• W1998957807 hasAuthorship W1998957807A5041200743 @default.
• W1998957807 hasAuthorship W1998957807A5056569468 @default.
• W1998957807 hasAuthorship W1998957807A5058936977 @default.
• W1998957807 hasAuthorship W1998957807A5059923524 @default.
• W1998957807 hasAuthorship W1998957807A5082853715 @default.
• W1998957807 hasAuthorship W1998957807A5086123605 @default.
• W1998957807 hasAuthorship W1998957807A5088012470 @default.
• W1998957807 hasBestOaLocation W19989578071 @default.
• W1998957807 hasConcept C104317684 @default.
• W1998957807 hasConcept C121608353 @default.
• W1998957807 hasConcept C126322002 @default.
• W1998957807 hasConcept C141071460 @default.
• W1998957807 hasConcept C143998085 @default.
• W1998957807 hasConcept C185592680 @default.
• W1998957807 hasConcept C197934379 @default.
• W1998957807 hasConcept C2775930923 @default.
• W1998957807 hasConcept C2776262904 @default.
• W1998957807 hasConcept C2778305200 @default.
• W1998957807 hasConcept C2778822529 @default.
• W1998957807 hasConcept C2779134260 @default.
• W1998957807 hasConcept C2779984678 @default.
• W1998957807 hasConcept C2780580376 @default.
• W1998957807 hasConcept C31760486 @default.
• W1998957807 hasConcept C530470458 @default.
• W1998957807 hasConcept C535046627 @default.
• W1998957807 hasConcept C55493867 @default.
• W1998957807 hasConcept C64927066 @default.
• W1998957807 hasConcept C71924100 @default.
• W1998957807 hasConcept C90924648 @default.
• W1998957807 hasConceptScore W1998957807C104317684 @default.
• W1998957807 hasConceptScore W1998957807C121608353 @default.
• W1998957807 hasConceptScore W1998957807C126322002 @default.
• W1998957807 hasConceptScore W1998957807C141071460 @default.
• W1998957807 hasConceptScore W1998957807C143998085 @default.

• next